QLS12010 clinical trials
Also written QLS12010.
How each study uses QLS12010 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the QLS12010 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QLS12010
- 4
Studies by the year they started
4 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Qilu Pharmaceutical Co., Ltd. (3) · Shanghai Qilu Pharmaceutical Research and Development Center LTD (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test QLS12010.
- Jun 2027QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis SuppurativaPhase 2 · Qilu Pharmaceutical Co., Ltd.
- Sep 2027A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic DermatitisPhase 2 · Qilu Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses QLS12010 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis SuppurativaNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07417917Written as QLS12010
- QLS12010 in Participants With Moderate-to-severe Rheumatoid ArthritisNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07377773Written as QLS12010
- A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic DermatitisNot yet recruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT07344051Written as QLS12010
- A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis PatientsRecruitingPhase 1Shanghai Qilu Pharmaceutical Research and Development Center LTDNCT06946641Written as QLS12010